Introduction. COVID-19 is an extreme challenge to health systems around the world. Patients with hematological disorders (HD) are known to be more predisposed to and have higher morbidity and mortality rates from COVID-19 than the general population. The aim of the present study was to analyze the clinical evolution of patients with HD who contracted COVID-19. Material and methods. The study included 111 patients with various HD who contracted COVID-19 between April 2020 and March 2021, being monitored in the Hematology Center of the Oncology Institute in Chisinau, Republic of Moldova. The cases were evaluated to analyze the impact of this pathology on the hematological patient (HP). Results. In the study group, 52 (46.8%) were women and 59 (53.2%) men. The mean age of the patients was 57.2±13.1 years. The HD associated with COVID-19 were: non-Hodgkin's lymphoma (NHL) – 56 pts (50.45%), multiple myeloma – 18 pts (16.22%), acute leukemia - 12 pts (10.81%), Hodgkin lymphoma – 9 pts (8.11%), idiopathic myelofibrosis – 6 pts (5.41%), chronic lymphocytic leukemia – 5 pts (4.5%), others – 5 pts (4.5%). Mild forms of COVID-19 were established in 17 pts (15.3%), moderate in 43 pts (38.7%), severe in 51 pts (45.9%). SARSCoV2 pneumonia was found in 86 (77.5%) cases. SARS-CoV-2 mortality in the study group was 42 (38.2%) cases. Among the predictors of severe forms were: active disease, old age, use of monoclonal antibodies and intensive chemotherapy. From patients who overcame COVID-19 in 8 (7.3%) cases, the progression of hematological disease was found during the of COVID-19. Conclusions. HP are a sensitive population to SARS-CoV-2 infection. The most common HD associated with COVID-19 was NHL (50.45%). Severe forms of COVID-19 were detected in 45.9% of cases. The mortality associated with SARS-CoV2 infection was 38.2%.